Crystals
Obtaining the crystal of 4,6-dimethyl-4′-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]nicotinanilide having excellent activity of inhibiting Ca 2+ release-activated Ca 2+ channel and suppressing IL-2 production to find that the compound includes the presence of two types of polymorphic crystals and that any of the crystals is preferable as a raw material for producing pharmaceutical compositions.
1. A crystal of 4,6-dimethyl-4′-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]nicotinanilide.
2. The crystal according to claim 1 , which has peaks of 2θ (°) at 5.94, 9.94, 15.64, 15.88, 18.48, 20.04 and 20.76 in X-ray powder diffraction.
3. The crystal according to claim 1 , which has peaks of 2θ (°) at 10.60, 12.90 and 17.24 in X-ray powder diffraction.
4. The crystal according to claim 1 , which has a thermal absorption peak at 195 to 198° C. (onset) in DSC analysis.
5. The crystal according to claim 2 , which has a thermal absorption peak at 195 to 198° C. (onset) in DSC analysis.
6. The crystal according to claim 3 , which has a thermal absorption peak at 195 to 198° C. (onset) in DSC analysis.